San Francisco, USA and Suzhou, China, September 2, 2024 / PRNewswire / -- Innovent Biologics Group (Stock Code: 01801) (hereinafter referred to as 'Innovent'), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs in the fields of cancer, autoimmunity, metabolism, cardiovascular, and ophthalmology, announced that multiple clinical study data of Martisdupanib will be presented as an oral presentation at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD). The latest data includes the results of the DREAMS-2 Phase III registration clinical study of Martisdupanib for type 2 diabetes, which will be presented as a Late Breaking Abstract (LBA) oral presentation. The conference will be held in Madrid, Spain from September 9th to 13th, 2024. Specific information is as follows:

Title: Results of a 28-week Phase III randomized, open-label trial comparing Martisdupanib with Dulaglutide in patients with type 2 diabetes (DREAMS-2)

Abstract number: LBA 16

Presentation format: Late Breaking Abstract oral presentation

Time: September 11th, 4:15 - 4:30 PM (local time)

Speaker: Professor LiXin Guo, Peking Hospital

Title: Phase III study results of Masitinib in Chinese overweight or obese population (GLORY-1)

Abstract Number: 149

Presentation format: Oral report

Time: September 12th, 11:45 - 12:00 AM (local time)

Speaker: Professor Lining Ji, Peking University People's Hospital

Title: Exploration Analysis of the GLORY-1 Study on the Improvement of Hepatic Fat Deformation in Overweight or Obese Chinese Subjects by Marseudopeptide

Summary Number: 744

Presentation Format: Brief Oral Report

Time: September 10, 12:30 PM (local time)

Speaker: Professor Gaolei Beijing University People's Hospital

Title: Phase II study of Maceptide 9mg in Chinese adult subjects with BMI≥30 kg/m2

Abstract number: 733

Presentation format: Brief oral presentation

Time: September 12th, 14:00 (local time)

Speaker: Professor Jiang Hongwei, First Affiliated Hospital of Henan University of Science and Technology.

Dr. Qian Lei, Vice President of Clinical Development at Innovent Bio, said: "Following the release of the results of the GLORY-1 phase III study of masitinib for weight loss at the ADA conference in June, we are pleased to announce for the first time at the EASD conference the results of the DREAMS-2 phase III study of masitinib for diabetes as a significant breakthrough in the form of an oral presentation. Masitinib is the only dual GLP-1 and GCG receptor agonist currently conducting phase III studies for diabetes globally, and the DREAMS-2 study has demonstrated its superior glycemic and weight loss effects compared to dulaglutide. Additionally, several weight loss studies including GLORY-1 study and masitinib 9 mg phase II study will also be presented at this year's EASD conference in the form of oral presentations or brief oral presentations. The glycemic and weight loss effects of masitinib, as well as its reduction of liver fat and other comprehensive metabolic benefits, have been repeatedly proven and expanded in ongoing clinical exploration."

About Marshipide (IBI362)

Masitinib (IBI362) is a dual glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) agonist jointly developed by Innovent Bio and Eli Lilly and Co. As a analog of gastric acid-regulating peptide (OXM) naturally present in the human body, masitinib not only stimulates GLP-1R to promote insulin secretion, lower blood sugar, and reduce weight, but also activates GCGR to increase energy expenditure and enhance weight loss efficacy, while improving liver fat metabolism. Masitinib has shown excellent weight loss and blood sugar lowering effects, as well as reductions in waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improvements in insulin sensitivity, bringing multiple metabolic benefits in multiple clinical studies.

Marshipide currently has two NDAs accepted for review by the NMPA, including:

• Long-term weight control for adult patients with obesity or overweight;
• Blood glucose control for adult patients with type 2 diabetes.

Marshipide is currently being studied in five Phase III clinical trials, including:

• III-phase clinical trial (GLORY-1) conducted in overweight or obese Chinese subjects.
• Among them, the GLORY-1, DREAMS-1, and DREAMS-2 studies have all reached their endpoints and been successfully completed.
• Phase III clinical trial (DREAMS-1) conducted in Chinese patients with newly diagnosed type 2 diabetes;
• Phase III clinical trial (DREAMS-2) comparing marizomib and dulaglutide in Chinese type 2 diabetes subjects with poor glycemic control treated with oral medications;
• Phase III clinical trial (DREAMS-3) comparing marizomib and semaglutide in Chinese subjects with type 2 diabetes and obesity;

详情请访问公司网站： Biologics。

"Starting with trust and ending with action", developing high-quality biopharmaceuticals that the general public can afford is the ideal and goal of Innovent Biologics. Innovent Biologics was established in 2011 and is committed to the development, production, and sales of innovative drugs to treat major diseases such as tumors, metabolic diseases, and autoimmune diseases. On October 31, 2018, Innovent Biologics went public on the Main Board of the Hong Kong Stock Exchange with stock code: 01801. Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model. It has established a product chain including 23 new drug varieties, covering multiple disease areas such as tumors, metabolic diseases, and autoimmune diseases, of which 6 varieties have been selected for the national "Major New Drug Creation" special project, and 3 products (Sintilimab Injection, brand name: Tyvyt, English trademark: TYVYT; Bevacizumab Injection, brand name: Duligotong, English trademark: BYVASDA; Camrelizumab Injection, brand name: Sulinno, English trademark: SULINNO) have been approved.

Statement: Innovent Bio does not recommend unapproved drugs.

Forward-looking statements

These forward-looking statements are based on management's current views, assumptions, expectations, estimates, forecasts, and understandings of future events, which are inherently subject to risks, uncertainties, and other factors, some of which are beyond the company's control, and may be difficult to predict. Therefore, actual results may differ materially from those included in the forward-looking statements due to future changes and developments in our business, competitive environment, politics, economy, laws, and social circumstances.